MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Castle Biosciences Operating Income 2011-2026 | CSTL
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Castle Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.67 M | -68 M | -72.9 M | -40.1 M | -6.54 M | 7.33 M | -3.84 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.67 M | -72.9 M | -25 M |
Quarterly Operating Income Castle Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.8 M | -4.25 M | -27.9 M | - | 5.08 M | 5.01 M | -5.47 M | - | -9.64 M | -21.2 M | -31.5 M | - | -21.5 M | -3.97 M | -24.5 M | - | -11.8 M | -8.81 M | -4.28 M | - | -3.9 M | -645 K | 1.04 M | - | 4.43 M | 608 K | -322 K | - | -2.85 M | -2.67 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.08 M | -31.5 M | -7.65 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 19.02 | 0.21 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
DexCom
DXCM
|
598 M | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.38 | 6.36 % | $ 323 M | Israel |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
CareDx, Inc
CDNA
|
-203 M | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 99.74 | -0.18 % | $ 3.93 B | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.12 | - | $ 99.5 K | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
-444 M | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
NeoGenomics
NEO
|
-92.1 M | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
National Research Corporation
NRC
|
40 M | $ 18.77 | 0.64 % | $ 461 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 173.53 | -1.12 % | $ 19.3 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 6.8 | 1.19 % | $ 882 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 182.22 | -0.43 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 66.55 | -0.91 % | $ 4.61 B | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 136.07 | -1.13 % | $ 41.4 B | USA |
 |
Precipio
PRPO
|
-7.62 M | $ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.52 | 2.86 % | $ 5.79 M | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 7.44 | -0.13 % | $ 466 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 7.96 | -0.13 % | $ 472 M | USA |